|
|
|
Available: 0 |
List Price:$99.95 |
|
Other formats:
|
Edition: | 22th |
Publisher: | Jones & Bartlett Publishing |
ISBN: | 1-284-14350-3 (1284143503) |
ISBN-13: | 978-1-284-14350-8 (9781284143508) |
New Edition: | 1-284-17132-9 |
Old Edition: | 1-284-11718-9 |
Format: | Handbook |
Binding: | Softcover |
Copyright: | 2018 |
Publish Date: | 12/17 |
Volume: | 2018 |
Weight: | 3.79 Lbs. |
Pages: | 1712 |
Carton Quantity: | 10 |
Subject Class: | N-O (Oncologic Nursing) |
Remarks: | A New Edition of this Title is Available |
Brandon Hill: | This is a Brandon Hill Title |
Return Policy: | Returns accepted up to 6 months provided no other recalls or return restrictions apply. |
Contributing Authors: |
View
|
ProQuest Ebook Central: |
Available in ProQuest Ebook Centralâ„¢ View
|
|
|
|
ISSN Series: | Oncology Nursing Drug Handbook | Discipline: | + Nursing | Subject Definition: | Neoplasms-Nursing-Handbooks: Drug Therapy | NLM Class: | WY 49 | LC Class: | RC271 | Abstract: | Written especially for nurses caring for patients with cancer, the 2018 Oncology Nursing Drug Handbook uniquely expresses drug therapy in terms of the nursing process: nursing diagnoses, etiologies of toxicities, and key points for nursing assessment, intervention, and evaluation. Updated annually, this essential reference provides valuable information on effective symptom management, patient education, and chemotherapy administration. Completely revised and updated, the 2018 Oncology Nursing Drug Handbook includes separate chapters on molecular and immunologic/biologic targeted therapies. These chapters provide fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer. It also offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for recently FDA approved drugs. New drugs include: avelumab (Bavencio), brigatinib (Alunbrig), durvalumab (Imfinzi), enasidenib (Idhifa), metronidazole hydrochloride (Flagyl), midostaurin (Rydapt), neratinib (Nerlynx), niraparib (Zejula), olaratumab (Lartruvo), ribociclib (Kisqali), rituximab and hyaluronidase human injection (Rituxan Hycela injection), rucaparib (Rubraca), telotristat ethyl (Xermelo), and tisagenlecleucel (Kymriah). |
|
|
|
|
|
|
Follow Matthews Book Co. on:
Copyright © 2001-2024 Matthews Book Company - All rights reserved. - 11559 Rock Island Ct., Maryland Heights, MO, 63043 - (800) MED-BOOK
Matthews